Staci joined the RegDev team in May 2023 to spearhead the establishment of the Regulatory Affairs function to complement RegDev’s existing capabilities of serving clients in multiple aspects of the drug development process. She has more than 25 years of regulatory affairs experience across multiple therapeutic areas in the design, negotiation, and execution of global regulatory strategies that align with corporate goals to ensure developmental success.  Prior to joining RegDev, Staci held leadership roles at MEI Pharma, Inc., Trius Therapeutics (acquired by Cubist Pharmaceuticals in 2014), Amylin Pharmaceuticals (acquired jointly by Bristol Myers Squibb and Astra Zeneca in 2012) and other small to mid-size biopharmaceutical companies. She enjoys integrating with sponsors and their teams to ensure a seamless collaboration.